Phase II evaluation of Stereotactic Ablative Radiotherapy (SABR) and immunity in 11C-Choline-PET/CT-identified oligometastatic castration-resistant prostate cancer.

Outcomes for resistant metastatic castration-resistant prostate cancer (CRPC) are poor. Stereotactic ablative radiotherapy (SABR) induces anti-tumor immunity in clinical and preclinical studies, but immunological biomarkers are lacking.